应用机器学习来理解预测成年智力和发育障碍者心理健康支持药物治疗的因素
Matthew Bogenschutz1, Michael Broda2, Parthenia Dinora3
1School of Social Work, Virginia Commonwealth University, Richmond, USA.
Social work in mental health
|March 5, 2026
概括
智力和发育障碍 (IDD) 个体经常面临心理健康差异,导致心理药物使用增加. 机器学习确定了情绪,焦虑和行为支持需求作为IDD患者这种药物使用的关键预测因素.
科学领域:
- 医疗保健服务研究 医疗服务研究
- 精神病学是一个精神病学.
- 医疗保健中的机器学习
背景情况:
- 智力和发育障碍 (IDD) 个体经历了显著的健康差异,特别是在心理健康护理方面.
- 对IDD人群的心理健康护理的差异可能导致过度依赖精神药物,可能导致不良影响.
- 了解心理药物使用的预测因素对于改善IDD患者的心理健康支持至关重要.
研究的目的:
- 确定预测IDD患者在心理健康需求中使用药物治疗的关键因素.
- 利用机器学习来分析全面的数据集以发现这些预测因素.
- 为IDD社区更好的心理健康管理提供临床实践和政策的信息.
主要方法:
- 利用机器学习算法来分析来自美国单一州的2018-2022年综合数据集.
- 包括2907个观察结果和850个与健康和支持需求相关的变量.
- 该算法展示了强大的预测性能.
主要成果:
- 情绪,焦虑和精神疾病的存在强烈预测了药物治疗的使用.
- 记录的行为支持需求是药物使用的重要预测因素.
- 整体支持需求也为模型的预测准确性做出了重大贡献.
- 机器学习模型在识别可能使用精神药物药物的个体方面取得了很高的准确性.
结论:
- 心理健康状况和支持需求是影响IDD患者使用心理药物的关键因素.
- 机器学习提供了一种强大的工具,用于识别有风险的个体,并为目标干预提供信息.
- 这些发现对社会工作者和心理健康专业人员有直接影响,为IDD人口提供服务,指导更个性化和更有效的护理策略.
相关概念视频
Drug Therapy
346
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
346
Psychosis: Goals of Pharmacotherapy
645
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
645
Therapeutic Drug Monitoring: Affecting Factors
299
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
299
Intellectual Disability
907
Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
907
Modeling in Therapy
627
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
627
Drug Toxicity: Risk factors
65
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
65


